Musely secured $360 million in non-dilutive capital from General Catalyst's Customer Value Fund, a rare move for a company that's been cash flow positive for years. CEO Jack Jia initially wasn't seeking capital, having consistently turned down VC approaches to avoid diluting ownership. Unlike traditional venture funding, this deal resembles a revenue-share agreement rather than equity financing, allowing Musely to access capital without giving up stake.

The telemedicine platform, specializing in compounded treatments for skin, hair, and menopause care, has grown at 50% year-over-year and served 1.2 million patients. The funding will support customer acquisition efforts, addressing the high costs of scaling direct-to-consumer healthcare brands. Jia noted that reaching the next billion in revenue typically requires another billion in capital, making this financing critical for Musely's continued expansion.

Musely's approach to funding challenges industry norms. After raising just $20 million in 2014, the company has operated without additional equity capital for nearly a decade. By joining the General Catalyst portfolio alongside companies like Grammarly and Lemonade, Musely demonstrates how DTC healthcare companies can access substantial capital without sacrificing ownership or taking on costly debt, potentially reshaping funding strategies for similar ventures.